公开(公告)号：EP3134730A4

公开(公告)日：2018-01-17

申请号：EP15782996

申请日：2015-04-24

Applicant: IMMUSANT INC

Inventor： ANDERSON ROBERT P

IPC: A61K38/10 ,  A61P1/00

CPC classification number: A61K39/0008 ,  A61K38/168 ,  A61K2039/55 ,  A61K2039/577 ,  C07K7/06 ,  C07K7/08 ,  C07K14/55 ,  G01N33/5091 ,  G01N33/564 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/06 ,  G01N2800/50

Abstract: Provided herein are methods and kits for assaying antigen-specific T cell responses, such as rare autoantigen-specific T cell responses, by measuring a level of IP-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a T cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a T cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having Type 1 Diabetes (TID), Celiac disease or both.

公开(公告)号：EP3142664A4

公开(公告)日：2017-12-13

申请号：EP15792756

申请日：2015-05-15

Applicant: TRANSLATUM MEDICUS INC

Inventor： BOYD SHELLEY ROMAYNE

IPC: A61K31/416 ,  A61K49/00 ,  A61P27/02 ,  A61P27/12 ,  C12Q1/00

CPC classification number: A61K31/416 ,  A61K9/0048 ,  A61K39/3955 ,  A61K49/0004 ,  A61K49/0034 ,  A61K2039/505 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/76 ,  C12Y304/21046 ,  G01N33/5088 ,  G01N33/582 ,  G01N2333/521 ,  G01N2800/16

Abstract: Disclosed herein are methods, compounds, such as bindaret, and compositions that are useful for the diagnosis, treatment, or prevention of an ocular disorder, including the discovery of agents that are efficacious against these disorders. Also included is the use of a fluorescent compound in an amount effective to indicate the presence of said ocular disorder in order to determine the efficacity of said compounds used in the diagnosis, treatment or prevention of said ocular disorders.

公开(公告)号：EP3004883A4

公开(公告)日：2017-06-21

申请号：EP14808179

申请日：2014-06-05

Applicant: GEMVAX & KAEL CO LTD ,  KIM SANG JAE

Inventor： KIM SANG JAE

IPC: G01N33/563 ,  G01N33/574 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K31/7068 ,  A61K38/08 ,  A61K38/10 ,  G01N33/57438 ,  G01N33/57488 ,  G01N33/6893 ,  G01N2333/4737 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2800/24 ,  G01N2800/52 ,  G01N2800/7095

Abstract: Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1α, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.

Abstract translation: 公开了基于以下发现的方法：eotaxin，MIP1α和CRP的血清和血浆水平充当重要的生物标志物，其用于确定当用GV1001肽（EARPALLTSRLRFIPK;衍生自人类）免疫治疗癌症时启动癌症的免疫治疗的可行性 端粒酶蛋白），任选地当与用吉西他滨和卡培他滨的现有技术组合治疗组合时。 具体而言，本发明提供了确定患者是否应该接受GV1001治疗以及确定是否应该继续进行煽动治疗的方法。

公开(公告)号：EP3073268A1

公开(公告)日：2016-09-28

申请号：EP15161465.8

申请日：2015-03-27

Applicant: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

Inventor： Brenner, Hermann ,  Chen, Hongda

IPC: G01N33/574

CPC classification number: G01N33/57488 ,  G01N33/57419 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2333/521 ,  G01N2333/525 ,  G01N2333/5412 ,  G01N2333/57 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2333/912 ,  G01N2333/95 ,  G01N2800/52 ,  G01N2800/60 ,  G01N2800/7028

Abstract: The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer in a patient. The method is based on the determination of the level of a panel of biomarkers selected from CEA, AREG, IL-6, GDF-15, HGF-receptor, CXCL9, ErbB4-Her4, CXCL10, Flt3L, VEGFR-2, CD69, CXCL5, PSA, EMMPRIN, Cathepsin-D, Caspase-3, TNF-alpha, and INF-gamma. The new biomarker panel of the invention allows diagnosing and even stratifying various cancer diseases. Furthermore provided are diagnostic kits for performing the non-invasive methods of the invention.

Abstract translation: 本发明涉及用于诊断，预后，分层和/或监测患者癌症的治疗的新方法。 该方法基于选自CEA，AREG，IL-6，GDF-15，HGF受体，CXCL9，ErbB4-Her4，CXCL10，Flt3L，VEGFR-2，CD69，CXCL5的生物标志物组的水平的测定 ，PSA，EMMPRIN，组织蛋白酶D，半胱天冬酶-3，TNF-α和INF-γ。 本发明的新生物标志物组允许诊断甚至分层各种癌症疾病。 此外提供了用于执行本发明的非侵入性方法的诊断试剂盒。

公开(公告)号：EP2831280A4

公开(公告)日：2016-02-24

申请号：EP13768451

申请日：2013-03-14

Applicant: HOFFMANN LA ROCHE

Inventor： ABBAS ALEXANDER R ,  ARRON JOSEPH R ,  CHANDRIANI SANJAY ,  JIA GUIQUAN ,  LEWIN-KOH NICHOLAS J I ,  DEPIANTO DARYLE

IPC: C12Q1/68 ,  A61K38/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/24 ,  G01N33/53 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/244 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/521 ,  G01N2333/775 ,  G01N2333/96494 ,  G01N2800/12 ,  G01N2800/52

Abstract: Compositions, kits and methods for assessing the prognosis of idiopathic pulmonary fibrosis in patients are provided. In addition, compositions, kits and methods for diagnosing subtypes of idiopathic pulmonary fibrosis are provided. Also provided are methods for treating idiopathic pulmonary fibrosis.

公开(公告)号：EP2201384B1

公开(公告)日：2015-07-15

申请号：EP08830897.8

申请日：2008-09-10

Applicant: Universiteit Leiden ,  Academisch Ziekenhuis Leiden Acting Under The Name Leiden University Medical Center

Inventor： BIESSEN, Ericus Anna Leonardus ,  VAN BERKEL, Theodorus Josephus Cornelis ,  KRAAIJEVELD, Adriaan Otto

IPC: G01N33/68 ,  A61P9/00

CPC classification number: G01N33/6863 ,  C07K14/523 ,  C07K16/24 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/53 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2500/10 ,  G01N2800/226 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  H01J49/0027 ,  H01J49/164 ,  H01J49/40

公开(公告)号：EP2748198A2

公开(公告)日：2014-07-02

申请号：EP12769299.4

申请日：2012-09-27

Applicant: The United States of America, as represented by The Secretary, Department of Health and Human Services

Inventor： BIELEKOVA, Bibiana ,  HERMAN, Matthew, L.

IPC: C07K16/28 ,  G01N33/53 ,  A61P25/00 ,  A61P37/06

CPC classification number: C07K16/2887 ,  A61K9/0085 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  G01N33/6863 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/521 ,  G01N2333/5434 ,  G01N2800/285 ,  G01N2800/52

Abstract: Described herein are methods of treating multiple sclerosis (MS), such as secondary progressive MS (SPMS), by intrathecally administering a B cell depleting agent, such as rituximab, alone or in combination with intravenous administration of a B cell depleting agent. Also described is the use of IL-12p40, CXCL13, or both as CSF biomarkers for selecting a patient with progressive MS as a candidate for treatment with an intrathecal immunomodulatory therapy, and for identifying a progressive MS patient as having meningeal inflammation. The present disclosure also describes a method of evaluating the effectiveness of a therapy for treating progressive MS by measuring the level of IL-12p40, CXCL13, or both in the CSF of the patient before and after treatment. A decrease in the level of IL-12p40, CXCL13, or both after treatment indicates the therapy is effective for treating progressive MS.

公开(公告)号：EP2640744A4

公开(公告)日：2014-05-28

申请号：EP11841462

申请日：2011-11-18

Applicant: EISAI R&D MAN CO LTD

Inventor： IMAI TOSHIO ,  KLINE BRAD ,  KAWANO TETSU ,  GRASSO LUIGI ,  SAKAMOTO YOSHIMASA ,  SPIDEL JARED ,  NISHIMURA MIYUKI ,  MURAMOTO KENZO ,  HORIZOE TATSUO

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04

CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863 ,  G01N2333/521

公开(公告)号：EP2652507A2

公开(公告)日：2013-10-23

申请号：EP11848773.5

申请日：2011-12-13

Applicant: Morehouse School of Medicine

Inventor： LILLARD, James, W. ,  SINGH, Shailesh ,  SINGH, Rajesh

IPC: G01N33/574 ,  G01N33/68 ,  G01N33/53

CPC classification number: G01N33/57496 ,  C07K16/24 ,  C07K16/2866 ,  C07K2317/73 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57426 ,  G01N33/5743 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/7158 ,  G01N2800/52

Abstract: Methods for detecting cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprise CCL25 or CCR9 or both CCL25 and CCR9.

公开(公告)号：EP2640744A2

公开(公告)日：2013-09-25

申请号：EP11841462.2

申请日：2011-11-18

Applicant: Imai, Toshio ,  Kline, James Bradford ,  Kawano, Tetsu ,  Grasso, Luigi ,  Sakamoto, Yoshimasa ,  Spidel, Jared ,  Nishimura, Miyuki ,  Muramoto, Kenzo ,  Horizoe, Tatsuo

Inventor： Imai, Toshio ,  Kline, James Bradford ,  Kawano, Tetsu ,  Grasso, Luigi ,  Sakamoto, Yoshimasa ,  Spidel, Jared ,  Nishimura, Miyuki ,  Muramoto, Kenzo ,  Horizoe, Tatsuo

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04

CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863 ,  G01N2333/521

Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.